RME Stock Chart & Stats
€202.90
€7.15(4.13%)
At close: 4:00 PM EDT
€202.90
€7.15(4.13%)
Day’s Range― - ―
52-Week Range€155.70 - €246.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.26B
Enterprise Value€27.61K
Total Cash (Recent Filing)€1.47B
Total Debt (Recent Filing)€825.92M
Price to Earnings (P/E)21.6
Beta0.57
Next Earnings
Oct 22, 2026EPS Estimate
2.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.44
Shares Outstanding144,252,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)4.28
Price to Sales (P/S)4.99
P/FCF Ratio17.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€210.65Price Target Upside3.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)10.53
Revenue Forecast (FY)€5.06B
Bulls Say, Bears Say
Bulls Say
Strong Growth And ProfitabilityResMed is growing revenue while expanding margins, indicating operating leverage and strong economics in its core business. This combination supports durable earnings growth and provides resources to fund innovation, market expansion, and shareholder returns over the next several quarters.
Connected Product EcosystemA broad installed base of devices, recurring mask demand, and connected software engagement can reinforce customer retention and create multiple revenue streams. Product adoption and higher compliance also strengthen ResMed’s ecosystem and support recurring demand beyond initial device sales.
Strong Balance Sheet And Cash GenerationLow leverage and strong cash conversion give ResMed financial flexibility to invest in products, pursue targeted acquisitions, and return capital without relying heavily on additional debt. A resilient balance sheet also improves the company’s ability to manage operational disruptions.
Bears Say
Astral Safety ActionThe Astral field-safety action is a structural near-term disruption because suspended sales directly reduce ventilator revenue and earnings. The issue may also require remediation and portfolio management, limiting growth while ResMed works through the corrective action and demand recovery.
Cash Flow And Investment PressureHigher investment in next-generation devices, AI, acquisitions, and marketing can support future growth but weighs on current cash expansion and margins. Recent free-cash-flow compression shows that increased spending and working-capital needs may reduce financial conversion over coming quarters.
MatrixCare Transition RiskSelling MatrixCare sharpens strategic focus, but the separation can create temporary execution complexity and stranded costs while shared services are unwound. The divestiture also removes a meaningful revenue and operating-profit contribution, increasing reliance on the core sleep and respiratory businesses.
Resmed News
RME FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was €155.70 and its highest was €246.50 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is €28.26B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Oct 22, 2026 which is in 31 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Aug 06, 2026. The company reported €2.536 earnings per share for the quarter, beating the consensus estimate of €2.487 by €0.049.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed does not currently pay dividends.
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.31.
How many shares outstanding does Resmed have?
Resmed has 144,252,300 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of €2.536 in its last earnings report, beating expectations of €2.487. Following the earnings report the stock price went down -10.904%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in DE:RME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€210.65 (3.82% Upside)
€210.65 (3.82% Upside)
Blogger Sentiment
Bullish
DE:RME Sentiment 78%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.80%
12-Months-Change
Fundamentals
Return on Equity
1.07%
Trailing 12-Months
Asset Growth
9.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Resmed
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RME Company Deck
RME Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid underlying growth and margin expansion across the core sleep business, strong full-year cash generation, material shareholder returns, and continued product and software momentum (masks, AirSense/AirCurve rollouts, GenAI MyAir, Oura partnership). Key negatives were a sizeable Astral field-safety provision and the suspension of Astral sales (driving significant ventilator revenue declines and near-term revenue/EPS headwinds), higher near-term R&D and SG&A investment, and Q4 free cash flow compression. Management provided explicit FY2027 revenue and EPS guidance, actions to return capital, and plans to prioritize high-ROI investments while actively managing the portfolio—presenting a constructive execution path despite the discrete Astral-related disruption.View all DE:RME earnings summariesRME Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RME Stock 12 Month Forecast
Average Price Target
€210.65
▲(3.82% Upside)